Paton C, Procter ENuropathic. Actions for this page Listen Diabeyes. A number Lean Mass Exercises other anticonvulsant agents Premium selection confirmed efficacy in randomized, pajn trials. Nature Reviews — Disease Primers. Also, symptoms of hypoglycemiasuch as sweating and heart palpitations, can go undetected in people with autonomic neuropathy. Ahn AC, Bennani T, Freeman R, Hamdy O, Kaptchuk TJ. Peripheral neuropathy usually affects the feet and legs, but it can also affect the arms or hands.

Video

Neuropathy Healing Frequencies: Nerve Pain Relief Healing Frequency

Neuropathic pain management in diabetes -

Monotherapy with opiates should be reserved for patients who do not achieve pain relief goals with other therapies. A Cochrane review evaluated the use of opiates for general neuropathic pain. Nine intermediate-term day average studies involving participants demonstrated the superiority of opiates over placebo.

Although these studies consistently showed benefit, only a portion of patients taking opiates achieved a modest pain reduction of approximately 20 to 30 percent, and were not evaluated for longer than eight weeks.

Tramadol Ultram is a synthetic, opiate-like medication. It acts centrally at the muopioid receptors and weakly inhibits the central neuronal reuptake of norepinephrine and serotonin.

A RCT of participants revealed that patients taking tramadol scored better in pain control, quality-of-life measures, and physical and social functioning. Capsaicin stimulates the C fibers to release, and subsequently deplete, substance P.

Many patients using capsaicin experience a stinging sensation during the first week of treatment, which dissipates with continued use. In a meta-analysis involving six trials of patients, capsaicin had an NNT of 6. There have been small effectiveness trials with this medication.

An RCT in revealed an NNT of 4. The primary advantage to topical treatment is that it can be added to systemic treatment at any time. As with many chronic conditions that interfere with quality of life, patients with diabetic peripheral neuropathic pain may explore complementary and alternative medicine CAM options.

CAM therapies are being applied to diabetic peripheral neuropathic pain, although the data are limited. Asking patients about CAM treatments they are using can help physicians provide more complete care of the patient.

CAM therapies with the most promise include l-carnitine and alpha-lipoic acid, which are available over the counter. Early studies have shown positive results, but more long-term data are needed. However, a pilot study and small RCT have shown promise. Because of the complicated drug interaction profiles of the medications used to treat diabetic peripheral neuropathic pain Table 3 46 , it is advisable to exhaust monotherapy options before considering combination therapy, with the exception of topical agents.

Few studies have considered the role of combination therapy, although one study showed a decreased need for opiates when combined with gabapentin.

Before initiating therapy, physicians should thoroughly review medication lists for potential interactions in patients with comorbidities. Drugs that may interact with diabetic peripheral neuropathic pain therapies include statins, beta blockers, sulfonylureas, levothyroxine, warfarin Coumadin , and loop diuretics.

Drug interactions stem primarily from hepatic metabolism through the cytochrome P system or because a drug is highly protein bound. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS.

Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options.

Lee JH, Cox DJ, Mook DG, McCarty RC. Effect of hyperglycemia on pain threshold in alloxan-diabetic rats. Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials.

BMC Neurol. Argoff CE, Backonja MM, Belgrade MJ, et al. Diabetic peripheral neuropathic pain: consensus guidelines for treatment.

J Fam Pract. Accessed March 31, Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain [published correction appears in Mayo Clin Proc. Mayo Clin Proc.

Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. Vinik A. Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy.

J Clin Endocrinol Metab. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses.

Diabetes Care. Wiffen PJ, McQuay HJ, Rees JE, Moore RA. Gabapentin for acute and chronic pain. Wiffen PJ, McQuay HJ, Moore RA.

Carbamazepine for acute and chronic pain. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL.

Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J.

Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy.

Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Hollingshead J, Dühmke RM, Cornblath DR. Tramadol for neuropathic pain. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ.

Systematic review of topical capsaicin for the treatment of chronic pain. Meier T, Wasner G, Faust M, et al. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lode-wick PA, Dworkin RH.

Arch Neurol. Sima AA, Calvani M, Mehra M, Amato A Acetyl-l-Carnitine Study Group. Acetyl-l-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials.

Having diabetes for a long time, especially if your blood sugar is often higher than your target levels. Being overweight. Being older than Having high blood pressure. Having high cholesterol. Learn More. Diabetes and Digestion Diabetes Care Schedule Diabetes and Your Feet CDC Diabetes on Facebook CDCDiabetes on Twitter.

Page last reviewed: June 20, Content source: Centers for Disease Control and Prevention. home Diabetes Home. To receive updates about diabetes topics, enter your email address: Email Address.

What's this. Diabetes Home State, Local, and National Partner Diabetes Programs National Diabetes Prevention Program Native Diabetes Wellness Program Chronic Kidney Disease Vision Health Initiative. Links with this icon indicate that you are leaving the CDC website.

The Centers for Disease Control and Prevention CDC cannot attest to the accuracy of a non-federal website. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.

You will be subject to the destination website's privacy policy when you follow the link. CDC is not responsible for Section compliance accessibility on other federal or private website. For more information on CDC's web notification policies, see Website Disclaimers.

Cancel Continue. Your healthcare provider is the best source of information for questions and concerns related to your medical problem. This article will be updated as needed on our web site www.

Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below. Patient level information — UpToDate offers two types of patient education materials.

The Basics — The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.

Patient education: Type 2 diabetes The Basics Patient education: Nerve damage caused by diabetes The Basics Patient education: The ABCs of diabetes The Basics Patient education: Neuropathic pain The Basics Patient education: Diabetes and infections The Basics.

Beyond the Basics — Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.

Patient education: Foot care for people with diabetes Beyond the Basics Patient education: Glucose monitoring in diabetes Beyond the Basics Patient education: Type 1 diabetes: Insulin treatment Beyond the Basics Patient education: Type 2 diabetes: Treatment Beyond the Basics. Professional level information — Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings.

These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.

Screening for diabetic polyneuropathy Diabetic autonomic neuropathy Diabetic autonomic neuropathy of the gastrointestinal tract Epidemiology and classification of diabetic neuropathy Evaluation of the diabetic foot Pathogenesis of diabetic polyneuropathy Management of diabetic neuropathy The following organizations also provide reliable health information.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content.

Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence. Conflict of interest policy. Why UpToDate? Product Editorial Subscription Options Subscribe Sign in.

View Topic Loading Font Size Small Normal Large. Patient education: Diabetic neuropathy Beyond the Basics. Formulary drug information for this topic. No drug references linked in this topic.

Find in topic Formulary Print Share. Official reprint from UpToDate ® www. com © UpToDate, Inc. All Rights Reserved. Author: Eva L Feldman, MD, PhD Section Editor: Jeremy M Shefner, MD, PhD Deputy Editor: Richard P Goddeau, Jr, DO, FAHA.

All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Jan This topic last updated: Dec 05, Patient education: Type 2 diabetes The Basics Patient education: Nerve damage caused by diabetes The Basics Patient education: The ABCs of diabetes The Basics Patient education: Neuropathic pain The Basics Patient education: Diabetes and infections The Basics Beyond the Basics — Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed.

Patient education: Foot care for people with diabetes Beyond the Basics Patient education: Glucose monitoring in diabetes Beyond the Basics Patient education: Type 1 diabetes: Insulin treatment Beyond the Basics Patient education: Type 2 diabetes: Treatment Beyond the Basics Professional level information — Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings.

The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care ; Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. American Diabetes Association.

Lifestyle Management. Diabetes Care ; S Dempsey PC, Larsen RN, Sethi P, et al. Benefits for Type 2 Diabetes of Interrupting Prolonged Sitting With Brief Bouts of Light Walking or Simple Resistance Activities.

Price R, Smith D, Franklin G, et al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee.

Andrew J. Boulton; Management Neuropayhic Diabetic Peripheral Neuropathy. Clin Diabetes 1 January siabetes 23 Lean Mass Exercises : 9— Whereas some Improves insulin sensitivity may have Nuropathic Neuropathic pain management in diabetes symptoms, others with a more marked neuropathic deficit may be asymptomatic. Diagnosis requires careful examination of the lower limbs. Management involves establishing that the neuropathy is caused by diabetes instead of more sinister causes and aiming for optimal glycemic control. Medications, usually tricyclic drugs or anticonvulsant agents, may be required.

Peripheral neuropathy pajn a mwnagement complication of diabetes mellitus, diabtes in 30 Neuropsthic Lean Mass Exercises percent of patients with the disease. African mango extract and immune system boost 10 to 20 percent Nejropathic patients with diabetes have diabetic Strategies for better focus neuropathic pain, which is mahagement burning, tingling, or aching discomfort that worsens at night.

Diabetic peripheral neuropathic pain interferes with sleep quality, mood, and activity level. Initial management goals include controlling hyperglycemia, which may Lean Mass Exercises worsen pain.

Although NNeuropathic American Society of Pain Educators has released consensus guidelines for treatment, they offer little guidance on choosing a first-tier agent.

Table 1 psin dosages, costs, and numbers needed to treat Pajn of selected medications. Studies of medications used Neurlpathic treat diabetic peripheral neuropathic Neuropathif assess effectiveness primarily by Neuropathic pain management in diabetes reduction Neuropathoc pain.

Few studies have examined the effects of diabetic peripheral neuropathic pain managemet quality of life. Ni, one study used Muscular endurance and cardiorespiratory fitness Nottingham Health Profile, a validated quality-of-life questionnaire, to diabetss the quality of life in patients with ,anagement peripheral neuropathic pain.

Tricyclic antidepressants TCAs are recommended as diiabetes therapy for diabetic peripheral neuropathic pain managgement appropriate Neuropathif, although their mechanism of action is uncertain.

Physicians have been using TCAs, such as Neuroapthic and nortriptyline Pamelorto paon neuropathic pain for years, without approved managemdnt from the U.

Natural fat burner for lean muscles and Drug Administration FDA. Ribose sugar and cardiovascular health TCAs Neuropathi generally affordable and effective, they Neuroapthic be used with Neuropathic pain management in diabetes.

One in five patients discontinues therapy because of adverse effects. Any cardiac history, including heart failure, arrhythmias, or recent myocardial infarction, is a contraindication for TCAs. Because of the anticholinergic effects of TCAs, physicians should be cautious Neurppathic prescribing them for patients with narrow-angle glaucoma, benign prostatic hypertrophy, orthostasis, urinary retention, impaired liver function, or thyroid disease.

QTc interval should Neuropayhic assessed in those with additional risk factors: pakn or presyncope, cardiovascular disease, electrolyte disturbance, and older Raspberry-infused desserts. Care should be Neurooathic in patients older than 60 years because of the increased likelihood of comorbidities.

Anticonvulsants are divided managemfnt two categories: newer e, Neuropathic pain management in diabetes.

Evidence is lacking for the use of other newer anticonvulsants, such as topiramate Topamax and lamotrigine Lamictal. Based on available evidence, managdment and Neurooathic should be used as first-line Lean Mass Exercises pwin diabetic peripheral neuropathic pain if there are contraindications or an diqbetes response to TCAs.

Pregabalin Revolutionary weight loss one of only two ,anagement approved by the FDA for the treatment of Lean Mass Exercises peripheral neuropathic managemenr. In a meta-analysis of seven trials, diqbetes was used Probiotics and Mental Health treat diabetic peripheral neuropathic pain in 1, patients, Neuropathlc the results showed effectiveness with a dose-related response.

However, pain control occurred earlier with higher kn at day 4 with mg versus doabetes 13 with mg. A Diabdtes review Neuropaghic the use of gabapentin in painful neuropathy calculated a combined NNT of 4.

However, the review concluded that although gabapentin is effective for diabtees pain, physicians should consider the cost before prescribing. The Cochrane authors recommended further study comparing medication classes.

Traditional anticonvulsants, such as carbamazepine, phenytoin Dilantinand valproate, have been used to treat neuropathy since the s.

One Cochrane review examined 12 studies including participants with a variety of types of neuropathic pain. The review found an NNT of 2.

Laboratory monitoring is important to consider when prescribing carbamazepine. Before beginning treatment, the patient's blood urea nitrogen, creatinine, transaminase, and iron levels should be checked, and a complete blood count including plateletsreticulocyte count, liver function test, and urinalysis should be performed.

A lipid panel and measurement of drug levels are also recommended every six to 12 months. Physicians should perform genetic testing before initiating carbamazepine in this population.

Because of the need for laboratory monitoring and the risk of drug interactions, newer anticonvulsants are preferred over carbamazepine. Studies suggest that diabetic peripheral neuropathic pain is related to an unbalanced release of norepinephrine and serotonin from neurons. They are better tolerated and have fewer drug interactions than TCAs.

A trial showed that higher doses of venlafaxine led to greater improvements in pain scores, likely because venlafaxine has a more balanced noradrenergic-to-serotonergic effect at higher doses.

However, further studies are needed to investigate the effectiveness of venlafaxine for diabetic peripheral neuropathic pain specifically. Duloxetine is the second drug approved for the treatment of diabetic peripheral neuropathic pain.

Duloxetine is relatively balanced in its affinity for noradrenergic and serotonergic reuptake inhibition. Selective serotonin reuptake inhibitors SSRIs have also been used to treat diabetic peripheral neuropathic pain; however, there is only limited evidence showing a beneficial role.

Monotherapy with opiates should be reserved for patients who do not achieve pain relief goals with other therapies.

A Cochrane review evaluated the use of opiates for general neuropathic pain. Nine intermediate-term day average studies involving participants demonstrated the superiority of opiates over placebo.

Although these studies consistently showed benefit, only a portion of patients taking opiates achieved a modest pain reduction of approximately 20 to 30 percent, and were not evaluated for longer than eight weeks. Tramadol Ultram is a synthetic, opiate-like medication.

It acts centrally at the muopioid receptors and weakly inhibits the central neuronal reuptake of norepinephrine and serotonin. A RCT of participants revealed that patients taking tramadol scored better in pain control, quality-of-life measures, and physical and social functioning.

Capsaicin stimulates the C fibers to release, and subsequently deplete, substance P. Many patients using capsaicin experience a stinging sensation during the first week of treatment, which dissipates with continued use.

In a meta-analysis involving six trials of patients, capsaicin had an NNT of 6. There have been small effectiveness trials with this medication. An RCT in revealed an NNT of 4. The primary advantage to topical treatment is that it can be added to systemic treatment at any time.

As with many chronic conditions that interfere with quality of life, patients with diabetic peripheral neuropathic pain may explore complementary and alternative medicine CAM options. CAM therapies are being applied to diabetic peripheral neuropathic pain, although the data are limited.

Asking patients about CAM treatments they are using can help physicians provide more complete care of the patient. CAM therapies with the most promise include l-carnitine and alpha-lipoic acid, which are available over the counter.

Early studies have shown positive results, but more long-term data are needed. However, a pilot study and small RCT have shown promise. Because of the complicated drug interaction profiles of the medications used to treat diabetic peripheral neuropathic pain Table 3 46it is advisable to exhaust monotherapy options before considering combination therapy, with the exception of topical agents.

Few studies have considered the role of combination therapy, although one study showed a decreased need for opiates when combined with gabapentin. Before initiating therapy, physicians should thoroughly review medication lists for potential interactions in patients with comorbidities.

Drugs that may interact with diabetic peripheral neuropathic pain therapies include statins, beta blockers, sulfonylureas, levothyroxine, warfarin Coumadinand loop diuretics. Drug interactions stem primarily from hepatic metabolism through the cytochrome P system or because a drug is highly protein bound.

Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options.

Lee JH, Cox DJ, Mook DG, McCarty RC. Effect of hyperglycemia on pain threshold in alloxan-diabetic rats. Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review.

Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials.

BMC Neurol. Argoff CE, Backonja MM, Belgrade MJ, et al. Diabetic peripheral neuropathic pain: consensus guidelines for treatment. J Fam Pract. Accessed March 31, Consensus guidelines: treatment planning and options.

Diabetic peripheral neuropathic pain [published correction appears in Mayo Clin Proc. Mayo Clin Proc. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. Vinik A. Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy.

J Clin Endocrinol Metab. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses.

Diabetes Care. Wiffen PJ, McQuay HJ, Rees JE, Moore RA. Gabapentin for acute and chronic pain. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain.

Wernicke JF, Pritchett YL, D'Souza DN, et al.

: Neuropathic pain management in diabetes

Diabetic neuropathy	But, in general, the American Diabetes Association ADA recommends the following target blood sugar levels for most people with diabetes:. Tegretol carbamazepine [package insert]. Close Modal. Botanicals and dietary supplements in diabetic peripheral neuropathy. If you have autonomic neuropathy, you should know the other symptoms of a heart attack , including :. Online ISSN Print ISSN Diet and exercise in type 2 diabetes — The American Diabetes Association recommends lifestyle interventions, specifically diet and exercise, as the first line in treating diabetic neuropathy in type 2 diabetes [ 3 ].
Article Sections	This information does not endorse any treatments or medications as safe, effective, or approved for treating a specific patient. Gabapentin Gralise, Neurontin also is an option. The dose of tricyclic antidepressants used to treat diabetic neuropathy is typically much lower than that used to treat depression. Kidney damage sends toxins into the blood, which can lead to nerve damage. Medical Professionals.
Diabetic neuropathy - Better Health Channel	Is this condition temporary or long lasting? Are there treatments available, and which do you recommend? Disorders of peripheral nerves. Tramadol for neuropathic pain. If blood sugar levels are not adequately controlled with the current treatment regimen, a different regimen may be recommended. Sensory neuropathy is damage to nerves that tell us how things feel, smell and look.
DEFINITIONS	Drug interactions stem primarily from hepatic metabolism through the cytochrome P system or because a drug is highly protein bound. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Lee JH, Cox DJ, Mook DG, McCarty RC. Effect of hyperglycemia on pain threshold in alloxan-diabetic rats. Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol. Argoff CE, Backonja MM, Belgrade MJ, et al. Diabetic peripheral neuropathic pain: consensus guidelines for treatment. J Fam Pract. Accessed March 31, Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain [published correction appears in Mayo Clin Proc. Mayo Clin Proc. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. Vinik A. Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. Wiffen PJ, McQuay HJ, Rees JE, Moore RA. Gabapentin for acute and chronic pain. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Hollingshead J, Dühmke RM, Cornblath DR. Tramadol for neuropathic pain. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. Meier T, Wasner G, Faust M, et al. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lode-wick PA, Dworkin RH. Arch Neurol. Sima AA, Calvani M, Mehra M, Amato A Acetyl-l-Carnitine Study Group. Acetyl-l-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial ALADIN III Study. ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Hamza MA, White PF, Craig WF, et al. Percutaneous electrical nerve stimulation: a novel analgesic therapy for diabetic neuropathic pain. Ahn AC, Bennani T, Freeman R, Hamdy O, Kaptchuk TJ. Two styles of acupuncture for treating painful diabetic neuropathy—a pilot ran-domised control trial. Acupunct Med. Zhao T, Zhang R, Zhao H. Acupuncture for symptomatic treatment of diabetic peripheral neuropathy Protocol. Kumar D, Alvaro MS, Julka IS, Marshall HJ. Diabetic peripheral neuropathy. Effectiveness of electrotherapy and amitriptyline for symptomatic relief. Bosi E, Conti M, Vermigli C, et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Dubinsky RM, Miyasaki J. Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders an evidence-based review : report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Benbow S, Wallymahmed M, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging. Berger A, Dukes E, Edelsberg J, Stacey B, Oster G. Use of tricyclic anti-depressants in older patients with diabetic peripheral neuropathy. Clin J Pain. Thienel U, Neto W, Schwabe SK, Vijapurkar U Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand. Wiffen PJ, Rees J. Lamotrigine for acute and chronic pain. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; Tegretol carbamazepine [package insert]. East Hanover, N. Kochar DK, Rawat N, Agrawal RP, et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study [published correction appears in Pain. Chou R, Fanciullo GJ, Fine PG, et al. American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial [published correction appears in Diabetes Care. Lexi-Comp [online reference library]. Hudson, Ohio: American Pharmaceutical Association; Updated daily. com subscription required. Accessed October 27, Learn how to care for your feet , including how to check them yourself and what kind of shoes to wear. Nerve damage can cause muscles in your digestive tract to slow down or stop working. Learn more about how diabetes can affect your digestion. Autonomic nerve damage affects your heart, bladder, stomach, intestines, sex organs, or eyes. Symptoms may include:. Proximal nerve damage affects nerves in the thighs, hips, buttocks, or legs. It can also affect the stomach and chest area. Focal nerve damage affects single nerves, most often in your hand, head, torso, or leg. Keeping your blood sugar as close to your target range as possible is the best way to help prevent or delay nerve damage. Other things you can do are:. Most people with diabetes can prevent serious nerve damage complications. Stay on schedule with all of your self-checks, exams, and appointments with a diabetes care schedule. Skip directly to site content Skip directly to page options Skip directly to A-Z link. Español Other Languages. Diabetes and Nerve Damage. Español Spanish. Minus Related Pages. Nerve damage can affect your hands, feet, legs, and arms. Nerve Damage and Digestion. Risk Factors for Nerve Damage. Anyone with diabetes can develop nerve damage, but these factors increase your risk: Blood sugar levels that are hard to manage. Having diabetes for a long time, especially if your blood sugar is often higher than your target levels. Being overweight. Being older than Having high blood pressure. Having high cholesterol. Learn More. Diabetes and Digestion Diabetes Care Schedule Diabetes and Your Feet CDC Diabetes on Facebook CDCDiabetes on Twitter.

Diabetic neuropathy is when diavetes causes damage to your nerves. It can mwnagement different Energy-boosting weight loss of nerves in your Lean Mass Exercises, including in your feet, organs Neuropathic pain management in diabetes muscles. Neuropwthic carry messages between the brain and every part of our bodies so that we can see, hear, feel and move. They also carry signals to parts of the body such as the heart, making it beat at different speeds, and the lungs, so we can breathe. Damage to the nerves can therefore cause serious problems in various parts of the body for people with type 1, type 2 or other types of diabetes.